Retatrutide Side Effects: Complete 2026 Guide With Phase 2 + 3 Trial Data

Direct answer: The most common retatrutide side effects are gastrointestinal — nausea ran 14.5% to 60% across the Phase 2 dose arms and 45.2% at 12 mg in that trial's posted registry results, and 43.2% at 12 mg in the Phase 3 TRIUMPH-4 topline. Vomiting was 19.4% at 12 mg in Phase 2 and 20.9% in TRIUMPH-4, dysesthesia (altered skin sensation) affected 20.9% at 12 mg in TRIUMPH-4 but 12.5% at 12 mg in the larger TRIUMPH-1 obesity trial, and heart rate rose 6.7 bpm on average at 12 mg in Phase 2 versus 0.9 bpm on placebo. Discontinuation for adverse events ran 3.8% to 18.2% across the four Phase 3 trials, depending on dose and population. Most retatrutide side effects spike during titration and settle at a stable maintenance dose — the patients who quit are usually the ones who push escalation too fast.

Retatrutide is still investigational. It is not approved in any country, and Lilly has said it plans to file for U.S. approval in Q1 2027, so every number below comes from clinical trials, not from a marketed product's label. If you are wondering how people are getting hold of it in the meantime, see our guide to where to buy retatrutide.

Retatrutide side effects follow a predictable arc that almost every patient repeats: rough during the first 1–2 weeks after each dose increase, then steadily better at a stable dose. The problem is that most people don't know that going in, and they panic and quit right when their body would have adapted.

Retatrutide Side Effects: The Complete List With Trial Frequencies

This is the single table most people come here for. Two things about it are worth reading before the numbers. First, the Phase 2 column comes from the posted ClinicalTrials.gov results for the Phase 2 obesity trial (Jastreboff et al., NEJM 2023; 338 participants, 48 weeks, 62 people in the 12 mg arm), which only lists non-serious events reaching 5% in at least one group — anything below that threshold shows as "not reported," which is not the same as zero. Second, the Phase 3 columns come from Lilly topline press releases, not peer-reviewed papers; detailed results for all four TRIUMPH trials are still awaiting publication.

Two notes on that table. Phase 2 did not use the MedDRA term "dysesthesia" — it coded the related skin-sensation events separately, and the pharmacovigilance review in European Journal of Clinical Pharmacology summarises the Phase 2 result as cutaneous hyperesthesia and skin sensitivity in about 7% of retatrutide-treated participants versus 1% on placebo. And the placebo column belongs to TRIUMPH-4 specifically; TRIUMPH-1's placebo arm ran higher on several events (nausea 14.8%, diarrhea 13.5%, constipation 10.9%, vomiting 4.8%, dysesthesia 0.9%), which is a normal feature of different populations, not a contradiction.

Retatrutide Side Effects: Phase 2 vs Phase 3 Data Side-by-Side

Most retatrutide content online still cites Phase 2 numbers exclusively, and a lot of what does cite Phase 3 quotes TRIUMPH-4 as though it were the whole Phase 3 record. It is not. Four registration trials have reported topline safety, in four different populations:

At 12 mg, the same event lands in a different place in each one. Nausea: 42.4% in TRIUMPH-1, 28.0% in TRIUMPH-2, 22.4% in TRIUMPH-3, 43.2% in TRIUMPH-4. Dysesthesia: 12.5%, 7.3%, 6.4%, 20.9%. Discontinuation for adverse events: 11.3%, 7.7%, 13.5%, 18.2%. If you are trying to decide whether to start, the honest read is a range, not a single figure.

The 60% Nausea Figure Belongs to a Different Dose

The most-quoted retatrutide side effects statistic is "60% nausea." That number is real, but it is not the 12 mg number. In the Phase 2 registry results, 60.0% nausea (21 of 35) occurred in the 8 mg group that started at 4 mg — the fast-titration arm. The 12 mg group's nausea rate was 45.2% (28 of 62), and the 1 mg arm's was 14.5%.

That detail matters more than the headline. The Phase 2 investigators' own conclusion was that gastrointestinal events were "partially mitigated with a lower starting dose (2 mg vs. 4 mg)," and the 60% figure is the evidence for it: the arm that escalated fastest, not the arm that ended highest, had the worst nausea.

Diarrhea Ran Higher in Phase 3

Phase 2 reported diarrhea in 14.5% of the 12 mg arm, against 11.4% on placebo — barely a signal. All four Phase 3 trials found more: 32.0% (TRIUMPH-1), 33.6% (TRIUMPH-2), 24.4% (TRIUMPH-3) and 33.1% (TRIUMPH-4) at 12 mg. The placebo arms also ran higher (8.7% to 13.5%), so part of the gap is population, but not all of it. Treat diarrhea as a first-tier retatrutide side effect, not a footnote.

Dysesthesia Was Smaller in Phase 2 — and Varies Between Phase 3 Trials

Phase 2 did not code dysesthesia as such; related skin-sensation events came to about 7% across retatrutide arms versus 1% on placebo. In Phase 3 the term was collected directly, and the results spread widely: 12.5% at 12 mg in TRIUMPH-1, 7.3% in TRIUMPH-2, 6.4% in TRIUMPH-3, and 20.9% in TRIUMPH-4 against 0.7% on placebo.

TRIUMPH-4 is the outlier and it is also the smallest trial, with roughly 148 people per arm. The 1-in-5 framing you will see quoted comes from that trial. The 2,339-participant obesity trial puts it closer to 1 in 8.

Meta-Analysis: Pooled Retatrutide Side Effects Across the Phase 2 Trials

A 2025 systematic review and meta-analysis in Proceedings (Baylor University Medical Center) pooled three randomized trials covering 878 patients total (748 retatrutide, 130 placebo). It predates all of the Phase 3 readouts, so it is a summary of the Phase 1b/2 record, not of the full evidence base. The pooled relative risks still give the cleanest dose-response picture of retatrutide side effects:

The meta-analysis lands on three clear messages about retatrutide side effects:

1. Vomiting is the most disproportionately elevated GI event — relative risks of 4.6× to 9× vs placebo. This is the side effect that drives most early discontinuations.
2. Headache, dyspepsia, and abdominal pain were NOT significantly elevated — the authors found "no significant correlation between the two groups" for those three across the pooled trials.
3. Discontinuation risk scales steeply with dose — 4 mg showed no significant excess discontinuation vs placebo; 12 mg carried 6.7× the placebo rate.

The pooled weight-loss number was −14.33% body weight across doses, with −16.90% at 12 mg specifically. For context, the Phase 3 obesity trial later reported −28.3% at 12 mg over 80 weeks, so the pooled Phase 2 figure understates what the drug does over a longer course.

Heart Rate: The Retatrutide Side Effect Worth Tracking Actively

GLP-1, GIP, and glucagon receptor activation all influence sympathetic tone. The net result is a modest, dose-dependent heart rate increase. The only published per-dose figures come from the Phase 2 obesity trial, as least-squares mean change at 48 weeks:

What the data shows specifically:

• Maximum average elevation was +6.7 bpm at 12 mg, against +0.9 bpm on placebo
• The NEJM report states that dose-dependent heart rate increases peaked at week 24 and declined thereafter
• No heart rate figures were included in any of the four Phase 3 toplines, so there is no published Phase 3 number to quote
• Arrhythmia rates were not reported at the 5% threshold in the Phase 2 registry results, and were not mentioned in the Phase 3 toplines — the "2–11% arrhythmia" figure circulating online has no traceable source
• Patients on retatrutide saw blood pressure improvements (−9.88 mmHg systolic, −3.88 mmHg diastolic in the meta-analysis; −14.0 mmHg systolic at the top dose in TRIUMPH-4)

On major cardiovascular events, the picture is now more informative than "none observed." TRIUMPH-3, which enrolled 1,949 people with severe obesity and established cardiovascular disease, reported 44 MACE-5 events on retatrutide versus 52 on placebo (HR 0.82, 95% CI 0.55 to 1.22) and 27 MACE-3 events versus 23 (HR 1.12, 95% CI 0.64 to 1.96). Both confidence intervals cross 1, so the trial neither demonstrated cardiovascular benefit nor established harm; Lilly noted MACE occurred less frequently than anticipated in both arms.

For most patients this is one of the lower-priority retatrutide side effects to worry about. If you have pre-existing arrhythmia, heart failure, or untreated high resting heart rate, it deserves a conversation with the prescriber.

Dysesthesia: The Retatrutide Side Effect Most Articles Miss

Dysesthesia is altered skin sensation — tingling, burning, "pins and needles," heightened pressure sensitivity, or sensitivity to heat or cold. It is one of the more distinctive retatrutide side effects, but it is not unique to retatrutide.

Phase 3 TRIUMPH-4 reported dysesthesia in:

• 0.7% of placebo patients
• 8.8% of 9 mg retatrutide patients
• 20.9% of 12 mg retatrutide patients

TRIUMPH-1, four times larger, reported 5.1%, 12.3% and 12.5% at 4, 9 and 12 mg against 0.9% on placebo. TRIUMPH-2 and TRIUMPH-3 landed lower still, at 7.3% and 6.4% for 12 mg.

The class comparison is the part most coverage gets wrong. The Wegovy prescribing information reports dysesthesia in 22% of patients on semaglutide 7.2 mg, 6% on 2.4 mg and 0.3% on placebo, and lists it as an adverse reaction at 2% in the pooled 2.4 mg obesity trials. The Zepbound label reports 0.2% to 0.4% on tirzepatide versus 0.1% on placebo. The 2026 pharmacovigilance analysis in European Journal of Clinical Pharmacology concluded that dysesthesia is dose-dependent, "occurring more frequently at higher doses and with more potent GLP-1R" agonists, and that it has been "observed in clinical trials of semaglutide, tirzepatide, and retatrutide."

Key facts about dysesthesia as a retatrutide side effect:

• Mild in most cases — Lilly reported the TRIUMPH-4 events as "generally mild" and rarely leading to treatment discontinuation
• In TRIUMPH-1 the majority resolved during treatment and most participants stayed on the drug
• Mechanism is not established. Published hypotheses include loss of subcutaneous adipose tissue, nutritional deficiencies in B vitamins and copper, and GLP-1 and GIP receptor expression in the peripheral nervous system. Attributing it to the glucagon receptor does not fit the semaglutide data, since semaglutide has no glucagon activity and shows the highest reported rate of the three drugs at its top dose
• Whether pre-existing peripheral neuropathy raises the risk has not been reported in any retatrutide trial

If dysesthesia becomes severe, persistent, or painful (vs simply odd), tell the prescriber. In the semaglutide 7.2 mg program, dose reduction or temporary interruption resolved events faster than leaving the dose unchanged, and 45% of those who were re-escalated saw the sensation return.

Bone Fracture and Kidney Stone Concerns

Two specific concerns have surfaced around retatrutide that deserve their own discussion. Both are consequences of how fast the weight comes off, and neither has retatrutide-specific trial data behind it yet.

Bone Fractures and Bone Density Loss

Rapid weight loss of any kind reduces bone mineral density, and retatrutide produces a lot of it: −24.2% at 12 mg over 48 weeks in Phase 2 and −28.3% over 80 weeks in TRIUMPH-1, with a prespecified extension reaching −30.3% at 104 weeks in participants who started with a BMI of 35 or higher.

What is actually on the record:

• No fracture appears among the serious adverse events or the non-serious events reaching the 5% reporting threshold in the Phase 2 registry results, and none of the four Phase 3 toplines mentions fracture or bone mineral density rates. Claims that fractures ran above placebo in the retatrutide trials do not trace to any published source
• No DXA body-composition data has been published for retatrutide in the obesity trials. TRIUMPH-3 includes a prespecified DXA substudy, which has not reported
• Across incretin drugs generally, a meta-analysis of randomized trials found roughly 25% of total weight lost is lean mass, with a DXA subset of STEP 1 as high as 40% for semaglutide
• Older adults at highest baseline fracture risk have the least margin for that loss

Dr. John Batsis (University of North Carolina) on retatrutide and rapid weight loss: "How much is too much weight loss is unknown, and we really need additional data and need studies to look at that... We need to be mindful of how much to push. Just because we can, doesn't mean we should." Batsis also described patients on similar weight-loss treatments who became frail and suffered fractures — a clinical observation, not a trial finding.

Kidney Stones

One trial participant lost nearly a third of their body weight in eight months and developed kidney stones, as reported by Diabetes.co.uk. That report is explicit that it remains uncertain whether the stones were caused by the rapid weight loss. It is a single case, not an incidence rate. The plausible mechanism is dehydration from GI side effects combined with metabolic shifts during very rapid weight loss. Sensible precautions:

• Hydrate aggressively — 80+ oz water daily, more during titration weeks
• Don't skip electrolytes — sodium, potassium, magnesium losses are real
• Monitor urine color (target light straw, not dark amber)
• If stones run in the family or you've had one before, mention it before starting

These aren't traditional pharmacological retatrutide side effects — they're metabolic consequences of the weight-loss velocity the drug produces. The risk applies to anyone losing weight that fast, which is part of why slow, monitored progression matters.

Women-Specific Retatrutide Side Effects: Menstrual Cycle, Fertility, Hair, Contraception

The core retatrutide side effects list is identical for women and men. What differs is the downstream impact on hormone-sensitive systems.

Are Retatrutide Side Effects in Women Different From Men?

Retatrutide side effects in women are the same list as in men. What changes is how often they get reported and how often they end treatment.

Start with the honest limitation: there is no published sex-split safety table for retatrutide. Here is exactly what the trial record does and does not contain.

Reviewers have pointed out something most coverage skips: nearly 50% of the Phase 2 obesity trial was male, against 32.5% men in SURMOUNT-1 and 25.9% in STEP 1. Since women lost more weight on retatrutide, the balanced enrollment likely dampened the headline 24.2% figure relative to the trials it gets compared against.

What the GLP-1 Class Data Says About Side Effects in Women

With no retatrutide-specific sex split, the next best evidence is the rest of the class. A 2025 review in Endocrinology pulled the sex comparisons out of the major GLP-1 trials:

The pattern is consistent enough to plan around. Women don't get a different set of side effects; they report the same ones more often and quit over them more often. The liraglutide exposure finding is the most likely mechanical explanation — a woman and a man at the same body weight are not necessarily getting the same effective dose.

Nothing about retatrutide suggests it breaks that pattern, though nothing in its trial record confirms it either. The practical translation for women starting it: treat the titration schedule as a ceiling, not a target. Extra weeks at each step cost nothing. Rushed escalation is what produces the discontinuation.

Menstrual Cycle Changes

Retatrutide has not been shown to directly act on reproductive hormones, and no menstrual endpoint was reported in any of its trials. But rapid weight loss, caloric restriction, and insulin sensitivity shifts affect period timing and flow. Commonly described patterns:

• Missed or delayed periods during aggressive weight loss weeks — especially when calories drop below maintenance significantly
• Lighter flow as body fat reduces (estrogen production drops with adipose loss)
• Cycle normalization in PCOS patients as insulin sensitivity improves — in GLP-1 trials in PCOS, improved menstrual regularity and lower free testosterone are consistent findings

If periods stop entirely for 3+ months, talk to a clinician. This is functional hypothalamic amenorrhea territory — fixable, but not normal.

Hair Shedding

Hair loss is one of the most-searched retatrutide side effects. It was not reported at the 5% threshold in the Phase 2 registry results and does not appear in any TRIUMPH topline, so there is no retatrutide incidence figure. In the approved drugs of the class it is a listed adverse reaction — 3% on semaglutide 2.4 mg versus 1% on placebo, and 4% to 5% on tirzepatide versus 1% — and in both cases the accepted explanation is telogen effluvium, temporary shedding triggered by the metabolic stress of rapid weight loss rather than direct drug toxicity. Pattern:

• Onset 2–3 months after a steep weight-loss period
• Diffuse shedding (not patchy)
• Resolves on its own once weight stabilizes
• Worse with low protein intake during the loss period

The speed of the weight loss, not the molecule, is the best-supported driver. Adequate protein, adequate iron, and slower titration all reduce the shedding intensity.

Oral Contraceptive Absorption

GLP-1 class medications slow gastric emptying. For tirzepatide this is a labeled interaction: the Zepbound prescribing information advises patients using oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose escalation, and notes that non-oral hormonal contraceptives are not affected. Retatrutide has no label, so the same precaution is an extrapolation, not an instruction — but it is the one most prescribers apply.

Practical guidance:

• A barrier method backup (condom, diaphragm) is reasonable for the first 4 weeks of treatment and for 4 weeks after each dose increase
• Persistent vomiting within 4 hours of an oral contraceptive counts as a missed pill — use backup that cycle
• IUDs, implants, and depot injections are unaffected — they don't depend on oral absorption

Fertility Can Return Faster Than Expected

This is the women-specific effect people are least prepared for. Retatrutide has not been studied as a fertility drug, but the metabolic changes it produces — large weight loss, lower circulating insulin — are the same changes that restore ovulation in women with PCOS or obesity-related anovulation.

The class evidence is direct. In a randomized trial of 176 women with PCOS, 12 weeks of exenatide followed by metformin produced a natural pregnancy rate of 43.6% versus 18.7% on metformin alone. Liraglutide trials reported improved bleeding ratios and reduced free testosterone. Reviewers note the reproductive effect frequently exceeds what the weight loss alone would predict, which points to direct ovarian involvement rather than a purely metabolic knock-on.

Read that alongside the oral contraceptive absorption issue above and the risk is obvious: fertility rising at the same moment the pill may be working less reliably. If pregnancy is not the goal, settle non-oral contraception before starting, not after a missed period.

Pregnancy

Retatrutide should not be used during pregnancy. Its trials excluded women who were pregnant, breastfeeding, or of childbearing potential without adequate contraception, and no human pregnancy data exists. There is no retatrutide label, so there is no official washout instruction either.

The 2 months before trying to conceive figure that circulates comes from the semaglutide label, which directs patients to discontinue at least 2 months before a planned pregnancy because of the drug's long half-life and states that it may harm an unborn baby. Applying it to retatrutide is a reasonable read-across: retatrutide's half-life is roughly 6 days from Phase 1 pharmacokinetics, and the usual floor for washout is five half-lives, about 30 days. Two months is roughly double the arithmetic minimum, which is the right side to err on. If pregnancy occurs unexpectedly, stop the drug and contact a prescriber.

Retatrutide Side Effects vs Semaglutide vs Tirzepatide

A frequent question: are retatrutide side effects materially worse than what people see on Ozempic/Wegovy or Mounjaro/Zepbound? This is a cross-trial comparison, not a head-to-head. No trial has ever randomized patients between these three drugs. The retatrutide column comes from Phase 2 and Phase 3 toplines; the tirzepatide and semaglutide columns come from the obesity indications on their FDA labels, in different populations with different placebo rates.

The honest read:

• Retatrutide side effects are heavier than tirzepatide at top doses on nausea, vomiting and dysesthesia
• Broadly comparable to semaglutide 2.4 mg on nausea and vomiting, lower on headache
• Dysesthesia is prominent with retatrutide but not exclusive to it — semaglutide 7.2 mg reports the highest rate of the three
• Discontinuation is higher at the top dose, but so is the weight loss. Again cross-trial: retatrutide −28.3% at 80 weeks in TRIUMPH-1, tirzepatide −20.9% at 72 weeks in SURMOUNT-1, semaglutide −14.9% at 68 weeks in STEP 1. Most patients reach a different cost-benefit conclusion than the side effect table alone suggests

The Retatrutide Side Effects Timeline: What to Expect and When

A typical patient's experience of retatrutide side effects follows a recognizable arc. In every Phase 3 trial the starting dose was 2 mg weekly, stepping up every four weeks (2 → 4 → 6 → 9 → 12 mg for the top dose), with 16 weeks of escalation followed by maintenance:

The single biggest predictor of completing treatment is whether the escalation pace matched the patient's tolerance. The Phase 2 result makes the point numerically: the fast-titration 8 mg arm had 60% nausea while the slow-titration 8 mg arm had 17.1%, at the same final dose.

How to Manage Retatrutide Side Effects: Practical Strategies

Most retatrutide side effects are manageable with predictable interventions. The items below are standard incretin side-effect management rather than trial-tested protocols for retatrutide specifically.

Nausea Management

• Inject at night. Nausea tends to be worst in the first day or two after a dose; sleeping through the early part improves perceived tolerability.
• Smaller, lower-fat meals. Fat slows gastric emptying further and worsens nausea on a GLP-1.
• Avoid alcohol for 48 hours after each dose. Compounds nausea, dehydration, and reflux.
• Stay upright for 1–2 hours after eating. Helps gastric content move.
• Anti-emetics as needed — ondansetron or metoclopramide on prescription; ginger and B6 OTC.

Vomiting Management

• Don't escalate the dose until vomiting has been absent for 7+ days.
• Hydration is non-negotiable — sip electrolyte fluids continuously rather than chugging water.
• Hold the dose if vomiting is preventing meals or fluid intake. This is not failure — it's the standard protocol.

Constipation Management

• Fiber + fluids. Soluble fiber (psyllium, oats, chia) plus 80+ oz water daily.
• Magnesium glycinate or citrate at bedtime helps without harsh stimulant laxatives.
• Walking after meals maintains gut motility.

Heart Rate Management

• Track resting heart rate weekly on a smart watch or BP cuff
• Discuss with prescriber if increase exceeds 15 bpm sustained for 4+ weeks — well above the +6.7 bpm trial average at the top dose
• Caffeine reduction during titration weeks can help if HR feels uncomfortable

Dysesthesia Management

• Most cases resolved during treatment in the Phase 3 trials
• Hold escalation if onset is during titration; in the semaglutide high-dose program, interruption or dose reduction resolved events faster than leaving the dose unchanged
• B-complex vitamin support is reasonable but not evidence-based for this indication
• Severe or painful dysesthesia warrants prescriber evaluation

Rare but Serious Retatrutide Side Effects to Know

These are uncommon but worth recognizing immediately if they occur:

Pancreatitis

Severe upper abdominal pain radiating to the back, with persistent nausea and vomiting, is the classic presentation. In the Phase 2 obesity trial, one confirmed serious event of acute pancreatitis occurred in the 12 mg arm — 1 of 62 participants, with none in any other arm or on placebo. None of the Phase 3 toplines reports a pancreatitis rate. Risk is generally considered higher in patients with:

• Prior pancreatitis history
• Gallstones (current or recent)
• Heavy alcohol use
• Triglycerides over 500 mg/dL

Worth knowing: the Phase 2 trial excluded anyone with a history of acute or chronic pancreatitis or symptomatic gallbladder disease, so the trial rate does not describe risk in those patients.

This is an ER visit, not a wait-and-see symptom.

Gallbladder Disease

In the Phase 2 registry results, one serious event of acute cholecystitis occurred, in an 8 mg arm — none in the 12 mg arm and none on placebo. No gallbladder event rate has been published from any Phase 3 trial. Symptoms: right upper quadrant pain (especially after fatty meals), nausea, jaundice. Risk is higher with rapid weight loss regardless of drug — another argument for slower titration.

Allergic / Hypersensitivity Reactions

In Phase 2, rash was reported in 3.2% of the 12 mg arm (with no cases on placebo) and pruritus in 1.6%; no hypersensitivity rate appears in the Phase 3 toplines. Most such events are mild. Anaphylaxis is a known rare risk for any injectable protein — facial/throat swelling or difficulty breathing is a 911 emergency.

Acute Kidney Injury

Not a direct drug effect — but dehydration from severe vomiting/diarrhea can precipitate AKI, especially in older adults or those on diuretics. One serious acute kidney injury event was recorded in an 8 mg arm in Phase 2. Aggressive hydration during early titration weeks is the prevention.

Thyroid C-Cell Tumors (Class Warning)

Retatrutide is not approved and therefore carries no boxed warning of its own. Every approved GLP-1 receptor agonist in this class does: rodent studies showed thyroid C-cell tumors, and human relevance remains unconfirmed. People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) were excluded from the retatrutide trials by protocol, and the same exclusion would be expected on any eventual label.

Severe Hypoglycemia

Hypoglycemia was not reported at the 5% threshold in the Phase 2 obesity trial, which excluded people with diabetes entirely. In TRIUMPH-2, conducted in people with type 2 diabetes, hypoglycemia was not among the most common adverse events reported in the topline. The practical risk rises when an incretin is used alongside insulin or sulfonylureas, which is the standard caution for the whole class and the most important one to plan for in T2D patients.

Is Retatrutide Safe?

Across the available data, retatrutide side effects are common but predominantly mild-to-moderate, and in the Phase 2 trial the serious adverse event rate was 3.7% on retatrutide and 4.3% on placebo. In TRIUMPH-3, the only trial powered to observe cardiovascular events, MACE occurred less often than expected in both arms and neither the MACE-5 nor MACE-3 hazard ratio was statistically distinguishable from 1. Bone fracture and kidney stone concerns are discussed above; both are tied to the velocity of weight loss rather than demonstrated drug toxicity, and neither has retatrutide trial rates behind it.

What is genuinely unknown:

• Long-term retatrutide side effects beyond 80 weeks — only TRIUMPH-1's prespecified 104-week extension goes further, and that was limited to 532 participants with a BMI of 35 or higher who had already tolerated their dose
• Detailed safety data — all four TRIUMPH safety profiles come from company toplines; none has been published in a peer-reviewed journal or posted to ClinicalTrials.gov yet
• Real-world adherence and tolerability outside the close monitoring of clinical trials (for aggregated user-reported experiences, see our roundup of retatrutide reviews)

What is fair to say: the retatrutide side effects profile is heavier than tirzepatide's but the weight loss is meaningfully greater. For most candidates, the trade-off looks favorable, especially with slow titration and good GI side-effect management — bearing in mind that the drug cannot legally be sold or prescribed today, and that anything sold as retatrutide outside a clinical trial is not a Lilly product.

Frequently Asked Questions About Retatrutide Side Effects

What are the most common retatrutide side effects? Nausea, vomiting, diarrhea, constipation, and decreased appetite — all gastrointestinal. TRIUMPH-4 rates at 12 mg: 43.2% nausea, 33.1% diarrhea, 25.0% constipation, 20.9% vomiting, 18.2% decreased appetite. TRIUMPH-1, the larger obesity trial, reported 42.4%, 32.0%, 26.1% and 25.3% for the first four.

Do retatrutide side effects go away? For most patients, yes. GI side effects peak during dose escalation and settle at a stable dose. Heart rate elevation peaked around week 24 in Phase 2 and then declined. Lilly reported that most dysesthesia events resolved during treatment, though a minority persist.

Are retatrutide side effects worse than Ozempic or Mounjaro? Against tirzepatide, yes on nausea, vomiting and dysesthesia. Against semaglutide 2.4 mg, roughly comparable on nausea and vomiting and lower on headache. Note this is a cross-trial comparison of separate trials in different populations, not a head-to-head study. The weight-loss numbers are also cross-trial: −28.3% (TRIUMPH-1, 80 weeks), −20.9% (SURMOUNT-1, 72 weeks), −14.9% (STEP 1, 68 weeks).

Can retatrutide cause hair loss? Indirectly, most likely. No hair loss rate has been reported in any retatrutide trial. In the approved drugs of the class it is listed at 3% (semaglutide 2.4 mg) and 4–5% (tirzepatide) versus 1% on placebo, and is attributed to telogen effluvium from rapid weight loss rather than direct drug toxicity. Adequate protein intake reduces severity.

Is dysesthesia from retatrutide permanent? Usually not. Lilly reported that the majority of events resolved during treatment and that they rarely led to discontinuation. In the semaglutide 7.2 mg trials, which collected the most detailed data on this event, 18% of affected patients had not reported recovery by the end of the trial — mostly those whose dose was left unchanged.

What should I do if retatrutide side effects are intolerable? Hold the current dose — don't escalate. The Phase 2 data supports this directly: at the same 8 mg target dose, the slow-titration arm had 17.1% nausea and the fast-titration arm had 60%. If side effects persist at the lower dose, a dose reduction is reasonable.

Are there long-term retatrutide side effects? The longest published exposure is 104 weeks, in a 532-person extension of TRIUMPH-1. Known longer-term concerns include bone density loss, lean mass loss, gallbladder disease, and the dose-dependent dysesthesia signal.

Is there a complete retatrutide side effects list? Yes — here is the full retatrutide side effects list ranked by TRIUMPH-4 frequency at 12 mg: nausea (43.2%), diarrhea (33.1%), constipation (25.0%), vomiting (20.9%), dysesthesia/altered skin sensation (20.9%) and decreased appetite (18.2%). Those six are the only events Lilly quantified in that topline. From the Phase 2 registry results at 12 mg, add fatigue (9.7%), dizziness (8.1%), headache (6.5%), allodynia (6.5%), hyperesthesia (3.2%) and rash (3.2%), plus a mean heart rate rise of 6.7 bpm. The phrase "side effects of retatrutide" or the misspelling "retatrutide side affects" refers to this same list.

Are "GLP-3 retatrutide side effects" different from regular retatrutide side effects? No. "GLP-3" is an informal nickname for retatrutide because it activates three receptors (GLP-1, GIP, glucagon) versus one for semaglutide. It is the same molecule (LY3437943), so GLP-3 retatrutide side effects are identical to retatrutide side effects: GI symptoms dominate, dysesthesia is prominent at the top dose, and heart rate rose 6.7 bpm on average at 12 mg in Phase 2.

Can retatrutide cause dehydration? Yes — dehydration is a recognized consequence of the nausea, vomiting, and diarrhea that reduce fluid intake, and the labels of the approved drugs in this class warn that it can lead to kidney problems. It is most likely during dose escalation when GI symptoms peak. Aim for 2–3L of water daily during titration weeks, and watch for dark urine, dizziness on standing, and persistent fatigue as early warning signs.

What are retatrutide injections side effects for women? Retatrutide injections side effects for women are the standard profile (nausea, vomiting, diarrhea, constipation, dysesthesia). No retatrutide trial has published adverse events split by sex, so any claim that the rates differ is an extrapolation from the wider GLP-1 class rather than a retatrutide finding. Patterns more commonly reported by women across that class include menstrual irregularities and increased hair shedding, both linked to rapid weight loss rather than a direct hormonal action.

Are retatrutide for-women before-and-after side effects different from men? The before-and-after side effects pattern for women on retatrutide appears broadly similar to men: GI symptoms peak during titration and settle at maintenance dose. There is no sex-stratified retatrutide safety data to confirm or refute that. Worth noting for women specifically: higher reported rates of menstrual changes and hair shedding across the class, both linked to rapid weight loss rather than direct drug action.

Can retatrutide cause irregular periods? Most likely as an indirect effect of rapid weight loss rather than a direct hormonal action — no menstrual endpoint was reported in any retatrutide trial. Commonly described changes include delayed cycles, shorter cycles, lighter flow, and missed periods, typically normalizing after weight loss plateaus. If irregular periods persist beyond 4–6 months at a stable maintenance dose, that warrants a hormonal workup with your prescriber.

Are retatrutide side effects in women different from men? Not in kind, and the frequency question is genuinely unanswered. Retatrutide has no published sex-stratified safety data: the Phase 2 trial enrolled 163 women out of 338 participants (48.2%) and stratified randomization by sex, but reported adverse events for the pooled cohort only, and the Phase 3 toplines do the same. Across the wider GLP-1 class, women report adverse effects more often (28% more than men on liraglutide, 41% more on dulaglutide) and are roughly twice as likely to discontinue for GI reasons. Women also lost more weight on retatrutide at the higher Phase 2 doses — −28.5% versus −21.9% in men. Assume the same side effect list, a higher chance of feeling it, and titrate slower.

Last reviewed: August 21, 2026

Sources

• Retatrutide Phase 2 obesity trial (NCT04881760) — posted results, ClinicalTrials.gov
• Triple–Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial — NEJM
• TRIUMPH-4 topline results, Dec 11 2025 — Eli Lilly
• TRIUMPH-1 and TRANSCEND-T2D-1 results, June 6 2026 — Eli Lilly
• TRIUMPH-2 and TRIUMPH-3 topline results, July 23 2026 — Eli Lilly
• TRIUMPH-4 trial record (NCT05931367) — ClinicalTrials.gov
• Efficacy and safety of retatrutide: systematic review and meta-analysis, Proc (Bayl Univ Med Cent) 2025 — PMC
• Triple Agonism Based Therapies for Obesity (Phase 1/2 heart rate and sex-split data) — PMC
• Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review, Eur J Clin Pharmacol 2026 — PMC
• WEGOVY (semaglutide) prescribing information — Novo Nordisk
• ZEPBOUND (tirzepatide) prescribing information — Eli Lilly
• Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era — PMC
• Retatrutide melts fat fast but at a cost warn experts — Diabetes.co.uk
• GLP-1 and Its Analogs: Does Sex Matter? — Endocrinology
• Retatrutide for obesity, OSA and knee osteoarthritis: rationale and design of the TRIUMPH trials — PMC
• GLP-1 Receptor Agonists in Reproductive Health: systematic review — PMC
• GLP-1 receptor agonists and preconception planning — PMC
• Retatrutide Side Effects — Noom
• Retatrutide Side Effects: Clinical Trial Data — Swolverine
• Retatrutide Side Effects: Complete Clinical Data — NiceRx
• Retatrutide Long-Term Side Effects — Bolt Pharmacy
• Retatrutide Side Effects — Doctronic
• Retatrutide Side Effects — Lola Health